Cargando…

Risk of Cancer After Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rh-BMP-2)

STUDY DESIGN. Retrospective cohort study among Medicare beneficiaries with lumbar spinal fusion surgery. OBJECTIVE. To determine the risk of subsequent cancer among patients who received recombinant human bone morphogenic protein (rhBMP) at surgery compared with those who did not. SUMMARY OF BACKGRO...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Gregory S., Kou, Tzuyung Doug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006942/
https://www.ncbi.nlm.nih.gov/pubmed/23883824
http://dx.doi.org/10.1097/BRS.0b013e3182a3d3b4
_version_ 1782314291609731072
author Cooper, Gregory S.
Kou, Tzuyung Doug
author_facet Cooper, Gregory S.
Kou, Tzuyung Doug
author_sort Cooper, Gregory S.
collection PubMed
description STUDY DESIGN. Retrospective cohort study among Medicare beneficiaries with lumbar spinal fusion surgery. OBJECTIVE. To determine the risk of subsequent cancer among patients who received recombinant human bone morphogenic protein (rhBMP) at surgery compared with those who did not. SUMMARY OF BACKGROUND DATA. rhBMP is commonly used to promote bone union after spinal surgery. BMP receptors are present on multiple cancer types, but the risk of cancer after receiving rhBMP has not been well studied. METHODS. We identified 146,278 subjects aged 67 years and older who underwent surgery in 2003 to 2008 and were followed through 2010 for a new diagnosis of 1 of 26 cancers. Proportional hazards models were used to determine cancer risk associated with rhBMP use. RESULTS. rhBMP was administered in 15.1% of the cohort. After an overall average follow-up of 4.7 years, 15.4% of rhBMP-treated and 17.0% of untreated patients had a new cancer diagnosis, with most commonly recorded types as prostate, breast, lung, and colorectal. In a multivariate proportional hazards model, there was no association of rhBMP with cancer risk (hazard ratio: 0.99, 95% confidence interval: 0.95–1.02). There was also no association of rhBMP with the risk of any individual cancer types. The results were consistent in analyses using 2 secondary definitions of incident cancer. CONCLUSION. In this large population-based analysis of Medicare beneficiaries, we found no evidence that administration of rhBMP at the time of lumbar fusion surgery was associated with cancer risk. Level of Evidence: 4
format Online
Article
Text
id pubmed-4006942
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-40069422014-05-01 Risk of Cancer After Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rh-BMP-2) Cooper, Gregory S. Kou, Tzuyung Doug Spine (Phila Pa 1976) Epidemiology STUDY DESIGN. Retrospective cohort study among Medicare beneficiaries with lumbar spinal fusion surgery. OBJECTIVE. To determine the risk of subsequent cancer among patients who received recombinant human bone morphogenic protein (rhBMP) at surgery compared with those who did not. SUMMARY OF BACKGROUND DATA. rhBMP is commonly used to promote bone union after spinal surgery. BMP receptors are present on multiple cancer types, but the risk of cancer after receiving rhBMP has not been well studied. METHODS. We identified 146,278 subjects aged 67 years and older who underwent surgery in 2003 to 2008 and were followed through 2010 for a new diagnosis of 1 of 26 cancers. Proportional hazards models were used to determine cancer risk associated with rhBMP use. RESULTS. rhBMP was administered in 15.1% of the cohort. After an overall average follow-up of 4.7 years, 15.4% of rhBMP-treated and 17.0% of untreated patients had a new cancer diagnosis, with most commonly recorded types as prostate, breast, lung, and colorectal. In a multivariate proportional hazards model, there was no association of rhBMP with cancer risk (hazard ratio: 0.99, 95% confidence interval: 0.95–1.02). There was also no association of rhBMP with the risk of any individual cancer types. The results were consistent in analyses using 2 secondary definitions of incident cancer. CONCLUSION. In this large population-based analysis of Medicare beneficiaries, we found no evidence that administration of rhBMP at the time of lumbar fusion surgery was associated with cancer risk. Level of Evidence: 4 Lippincott Williams & Wilkins 2013-10-01 2013-09-30 /pmc/articles/PMC4006942/ /pubmed/23883824 http://dx.doi.org/10.1097/BRS.0b013e3182a3d3b4 Text en © 2013 Lippincott Williams & Wilkins. http://creativecommons.org/licenses/by-nc-nd/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Epidemiology
Cooper, Gregory S.
Kou, Tzuyung Doug
Risk of Cancer After Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rh-BMP-2)
title Risk of Cancer After Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rh-BMP-2)
title_full Risk of Cancer After Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rh-BMP-2)
title_fullStr Risk of Cancer After Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rh-BMP-2)
title_full_unstemmed Risk of Cancer After Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rh-BMP-2)
title_short Risk of Cancer After Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rh-BMP-2)
title_sort risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-bmp-2)
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006942/
https://www.ncbi.nlm.nih.gov/pubmed/23883824
http://dx.doi.org/10.1097/BRS.0b013e3182a3d3b4
work_keys_str_mv AT coopergregorys riskofcancerafterlumbarfusionsurgerywithrecombinanthumanbonemorphogenicprotein2rhbmp2
AT koutzuyungdoug riskofcancerafterlumbarfusionsurgerywithrecombinanthumanbonemorphogenicprotein2rhbmp2